2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. FGFR

FGFR

Fibroblast growth factor receptor

FGFR

Related Products

PDF 1.46 MB

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-50904S1
    Nintedanib-13C,d3
    		Inhibitor 99.0%
    Nintedanib-13C,d3 is the 13C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib-<sup>13</sup>C,d<sub>3</sub>
  • HY-RS04911
    FGFR1 Human Pre-designed siRNA Set A
    		Inhibitor

    FGFR1 Human Pre-designed siRNA Set A contains three designed siRNAs for FGFR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    FGFR1 Human Pre-designed siRNA Set A
  • HY-160124
    Infigratinib-Boc
    		Inhibitor 98.29%
    Infigratinib-Boc is a derivative of Infigratinib containing a Boc (t-Butyloxy carbonyl) group. Infigratinib is an ATP-competitive pan-FGFR inhibitor.
    Infigratinib-Boc
  • HY-100818R
    Futibatinib (Standard)
    		Inhibitor
    Futibatinib (Standard) is the analytical standard of Futibatinib. This product is intended for research and analytical applications. Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM).
    Futibatinib (Standard)
  • HY-136849
    TL13-68
    		Inhibitor 98.88%
    TL13-68 is a biotin-tagged version of SM1-71, and it can be used to research the mechanism of SM1-71.
    TL13-68
  • HY-12965
    S49076
    		Inhibitor 99.44%
    S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
    S49076
  • HY-N0183S4
    Formononetin-d3-1
    		Inhibitor 99.67%
    Formononetin-d3-1 is the deuterium-labeled Formononetin (HY-N0183).
    Formononetin-d<sub>3</sub>-1
  • HY-162865
    FGFR2-IN-3
    		Inhibitor 98.28%
    FGFR2-IN-3 is an inhibitor of fibroblast growth factor receptor 2 (FGFR2). FGFR2-IN-3 has good binding properties, forming key interactions and inducing conformational changes in FGFR2. FGFR2-IN-3 can be used for research on tumors.
    FGFR2-IN-3
  • HY-P99823
    Recifercept
    Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia.
    Recifercept
  • HY-RS04918
    FGFR3 Human Pre-designed siRNA Set A
    		Inhibitor

    FGFR3 Human Pre-designed siRNA Set A contains three designed siRNAs for FGFR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    FGFR3 Human Pre-designed siRNA Set A
  • HY-RS04912
    Fgfr1 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Fgfr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fgfr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Fgfr1 Mouse Pre-designed siRNA Set A
  • HY-19981A
    Derazantinib Racemate
    		Inhibitor 99.38%
    Derazantinib Racemate (ARQ-087 Racemate) is the racemate of Derazantinib. Derazantinib is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.
    Derazantinib Racemate
  • HY-145723C
    MAX-40279 hemiadipate
    		Inhibitor 99.26%
    MAX-40279 hemiadipate is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate is also effective against the FLT3 mutants such as FLT3D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 hemiadipate inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hemiadipate can be used for the research of acute myelogenous leukemia (AML).
    MAX-40279 hemiadipate
  • HY-13311S
    Infigratinib-d3
    		Inhibitor 98.90%
    Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the FGFR family, with IC50 values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
    Infigratinib-d<sub>3</sub>
  • HY-W001179R
    2,5-Dihydroxybenzoic acid (Standard)
    		Inhibitor
    2,5-Dihydroxybenzoic acid (Standard) is the analytical standard of 2,5-Dihydroxybenzoic acid. This product is intended for research and analytical applications. 2,5-Dihydroxybenzoic acid is a derivative of benzoic and a powerful inhibitor of fibroblast growth factors.
    2,5-Dihydroxybenzoic acid (Standard)
  • HY-12009S
    Pazopanib-13C,d3 hydrochloride
    Pazopanib-13C,d3 (hydrochloride) is the deuterium and 13C labeled Pazopanib hydrochloride. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
    Pazopanib-<sup>13</sup>C,d<sub>3</sub> hydrochloride
  • HY-164853
    Kanglexin
    		99.65%
    Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.
    Kanglexin
  • HY-163985
    PROTAC FGFR2 degrader 1
    		Degrader
    PROTAC FGFR2 degrader 1 (compound N5) is a PROTAC that effectively targets FGFR2 with DC50 of 6.46 nM, the FGFR2 IC50 is 0.08 nM. PROTAC FGFR2 degrader 1 has anti-proliferative activity and highly selective, induces G0/G1 arrest of KATOIII and SNU16 cell cycle and inhibits apoptosis by reducing the activation of p-ERK and p-PLCγ, the downstream proteins of FGFR2. PROTAC FGFR2 degrader 1 inhibits gastric cancer cells remained above 50% at a concentration of 0.17 nM. PROTAC FGFR2 degrader 1 potently inhibits the growth of SNU16 xenograft tumors in mouse model (Structure Note: Pink, FGFR2 activator: HY-18708; Blue, E3 ligase ligand: HY--10984; Black, linker: HY-163989; E3 ligase ligand + linker：HY-163986) .
    PROTAC FGFR2 degrader 1
  • HY-13302C
    CP-547632 TFA
    		Inhibitor 99.42%
    CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy.
    CP-547632 TFA
  • HY-145043
    FGFR-IN-1
    		Inhibitor 99.46%
    FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219).
    FGFR-IN-1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity